Apogee Therapeutics, Inc.
APGE
$38.67
$2.326.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -237.67M | -205.39M | -182.15M | -146.66M | -118.49M |
| Total Depreciation and Amortization | 730.00K | 367.00K | 189.00K | 113.00K | 65.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.21M | 20.65M | 12.79M | 6.86M | 5.41M |
| Change in Net Operating Assets | -12.02M | -3.64M | -2.00M | 6.48M | 2.44M |
| Cash from Operations | -220.74M | -188.02M | -171.17M | -133.21M | -110.57M |
| Capital Expenditure | -5.84M | -5.12M | -1.15M | -1.32M | -569.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.07M | -230.62M | -299.31M | -385.20M | -473.79M |
| Cash from Investing | -8.90M | -235.74M | -300.46M | -386.52M | -474.36M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 46.16M | 44.98M | 494.88M | 450.52M | 766.12M |
| Repurchase of Common Stock | -32.66M | -32.81M | -32.81M | -33.03M | -363.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 33.05M | 33.05M | 33.05M | 33.05M | 1.69M |
| Cash from Financing | 46.54M | 45.21M | 495.11M | 450.54M | 767.46M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -183.11M | -378.54M | 23.47M | -69.20M | 182.52M |